Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1230.60
-14.90 (-1.20%)
< Home < Back

Dr. Reddy's launches Ciprofloxacin, Dexamethasone Otic Suspension in US Market

Date: 11-08-2020

Dr. Reddy’s Laboratories has launched Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA).

The Ciprodex brand had US sales of approximately $453 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health. The company’s Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle. 

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.